232 related articles for article (PubMed ID: 24918820)
21. Breast cancer genomes from CHEK2 c.1100delC mutation carriers lack somatic TP53 mutations and display a unique structural variant size distribution profile.
Smid M; Schmidt MK; Prager-van der Smissen WJC; Ruigrok-Ritstier K; Schreurs MAC; Cornelissen S; Garcia AM; Broeks A; Timmermans AM; Trapman-Jansen AMAC; Collée JM; Adank MA; Hooning MJ; Martens JWM; Hollestelle A
Breast Cancer Res; 2023 May; 25(1):53. PubMed ID: 37161532
[TBL] [Abstract][Full Text] [Related]
22. Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2*1100delC variant.
de Bock GH; Schutte M; Krol-Warmerdam EM; Seynaeve C; Blom J; Brekelmans CT; Meijers-Heijboer H; van Asperen CJ; Cornelisse CJ; Devilee P; Tollenaar RA; Klijn JG
J Med Genet; 2004 Oct; 41(10):731-5. PubMed ID: 15466005
[TBL] [Abstract][Full Text] [Related]
23. Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients.
Kilpivaara O; Bartkova J; Eerola H; Syrjäkoski K; Vahteristo P; Lukas J; Blomqvist C; Holli K; Heikkilä P; Sauter G; Kallioniemi OP; Bartek J; Nevanlinna H
Int J Cancer; 2005 Feb; 113(4):575-80. PubMed ID: 15472904
[TBL] [Abstract][Full Text] [Related]
24. Association between the CHEK2*1100delC germ line mutation and estrogen receptor status.
de Bock GH; Mourits MJ; Schutte M; Krol-Warmerdam EM; Seynaeve C; Blom J; Brekelmans CT; Meijers-Heijboer H; van Asperen CJ; Cornelisse CJ; Devilee P; Tollenaar RA; Klijn JG
Int J Gynecol Cancer; 2006; 16 Suppl 2():552-5. PubMed ID: 17010071
[TBL] [Abstract][Full Text] [Related]
25. Prognostic Significance of CHEK2 Mutation in Progression of Breast Cancer.
Ansari N; Shahrabi S; Khosravi A; Shirzad R; Rezaeean H
Lab Med; 2019 Jul; 50(3):e36-e41. PubMed ID: 31220302
[TBL] [Abstract][Full Text] [Related]
26. CHEK2 mutations and the risk of papillary thyroid cancer.
Siołek M; Cybulski C; Gąsior-Perczak D; Kowalik A; Kozak-Klonowska B; Kowalska A; Chłopek M; Kluźniak W; Wokołorczyk D; Pałyga I; Walczyk A; Lizis-Kolus K; Sun P; Lubiński J; Narod SA; Góźdż S
Int J Cancer; 2015 Aug; 137(3):548-52. PubMed ID: 25583358
[TBL] [Abstract][Full Text] [Related]
27. The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families.
Oldenburg RA; Kroeze-Jansema K; Kraan J; Morreau H; Klijn JG; Hoogerbrugge N; Ligtenberg MJ; van Asperen CJ; Vasen HF; Meijers C; Meijers-Heijboer H; de Bock TH; Cornelisse CJ; Devilee P
Cancer Res; 2003 Dec; 63(23):8153-7. PubMed ID: 14678969
[TBL] [Abstract][Full Text] [Related]
28. Survival from breast cancer in patients with CHEK2 mutations.
Huzarski T; Cybulski C; Wokolorczyk D; Jakubowska A; Byrski T; Gronwald J; Domagała P; Szwiec M; Godlewski D; Kilar E; Marczyk E; Siołek M; Wiśniowski R; Janiszewska H; Surdyka D; Sibilski R; Sun P; Lubiński J; Narod SA
Breast Cancer Res Treat; 2014 Apr; 144(2):397-403. PubMed ID: 24557336
[TBL] [Abstract][Full Text] [Related]
29. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
[TBL] [Abstract][Full Text] [Related]
30. CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer.
Weischer M; Nordestgaard BG; Pharoah P; Bolla MK; Nevanlinna H; Van't Veer LJ; Garcia-Closas M; Hopper JL; Hall P; Andrulis IL; Devilee P; Fasching PA; Anton-Culver H; Lambrechts D; Hooning M; Cox A; Giles GG; Burwinkel B; Lindblom A; Couch FJ; Mannermaa A; Grenaker Alnæs G; John EM; Dörk T; Flyger H; Dunning AM; Wang Q; Muranen TA; van Hien R; Figueroa J; Southey MC; Czene K; Knight JA; Tollenaar RA; Beckmann MW; Ziogas A; Christiaens MR; Collée JM; Reed MW; Severi G; Marme F; Margolin S; Olson JE; Kosma VM; Kristensen VN; Miron A; Bogdanova N; Shah M; Blomqvist C; Broeks A; Sherman M; Phillips KA; Li J; Liu J; Glendon G; Seynaeve C; Ekici AB; Leunen K; Kriege M; Cross SS; Baglietto L; Sohn C; Wang X; Kataja V; Børresen-Dale AL; Meyer A; Easton DF; Schmidt MK; Bojesen SE
J Clin Oncol; 2012 Dec; 30(35):4308-16. PubMed ID: 23109706
[TBL] [Abstract][Full Text] [Related]
31. Breast Cancer Family History and Contralateral Breast Cancer Risk in Young Women: An Update From the Women's Environmental Cancer and Radiation Epidemiology Study.
Reiner AS; Sisti J; John EM; Lynch CF; Brooks JD; Mellemkjær L; Boice JD; Knight JA; Concannon P; Capanu M; Tischkowitz M; Robson M; Liang X; Woods M; Conti DV; Duggan D; Shore R; Stram DO; Thomas DC; Malone KE; Bernstein L; ; Bernstein JL
J Clin Oncol; 2018 May; 36(15):1513-1520. PubMed ID: 29620998
[TBL] [Abstract][Full Text] [Related]
32. CHEK2 1100delC and Del5395bp mutations in BRCA-negative individuals from Serbian hereditary breast and ovarian cancer families.
Krivokuca A; Dobricic J; Brankovic-Magic M
J BUON; 2013; 18(3):594-600. PubMed ID: 24065469
[TBL] [Abstract][Full Text] [Related]
33. Chromosomal radiosensitivity of breast cancer with a CHEK2 mutation.
Baeyens A; Claes K; Willems P; De Ruyck K; Thierens H; Vral A
Cancer Genet Cytogenet; 2005 Dec; 163(2):106-12. PubMed ID: 16337852
[TBL] [Abstract][Full Text] [Related]
34. Germline CHEK2 Gene Mutations in Hereditary Breast Cancer Predisposition - Mutation Types and their Biological and Clinical Relevance.
Kleiblová P; Stolařová L; Křížová K; Lhota F; Hojný J; Zemánková P; Havránek O; Vočka M; Černá M; Lhotová K; Borecká M; Janatová M; Soukupová J; Ševčík J; Zimovjanová M; Kotlas J; Panczak A; Veselá K; Červenková J; Schneiderová M; Burócziová M; Burdová K; Stránecký V; Foretová L; Macháčková E; Tavandzis S; Kmoch S; Macůrek L; Kleibl Z
Klin Onkol; 2019; 32(Supplementum2):36-50. PubMed ID: 31409080
[TBL] [Abstract][Full Text] [Related]
35. Breast cancer risk is similar for CHEK2 founder and non-founder mutation carriers.
Leedom TP; LaDuca H; McFarland R; Li S; Dolinsky JS; Chao EC
Cancer Genet; 2016 Sep; 209(9):403-407. PubMed ID: 27751358
[TBL] [Abstract][Full Text] [Related]
36. Interaction between CHEK2*1100delC and other low-penetrance breast-cancer susceptibility genes: a familial study.
Johnson N; Fletcher O; Naceur-Lombardelli C; dos Santos Silva I; Ashworth A; Peto J
Lancet; 2005 Oct 29-Nov 4; 366(9496):1554-7. PubMed ID: 16257342
[TBL] [Abstract][Full Text] [Related]
37. CHEK2 1100DELC germline mutation: a frequency study in hereditary breast and colon cancer Brazilian families.
Abud J; Koehler-Santos P; Ashton-Prolla P; Prolla JC;
Arq Gastroenterol; 2012 Dec; 49(4):273-8. PubMed ID: 23329222
[TBL] [Abstract][Full Text] [Related]
38. Evaluating the role of CHEK2 p.(Asp438Tyr) allele in inherited breast cancer predisposition.
Kumpula TA; Koivuluoma S; Soikkonen L; Vorimo S; Moilanen J; Winqvist R; Mantere T; Kuismin O; Pylkäs K
Fam Cancer; 2023 Jul; 22(3):291-294. PubMed ID: 36653541
[TBL] [Abstract][Full Text] [Related]
39. Missense mutations (p.H371Y, p.D438Y) in gene CHEK2 are associated with breast cancer risk in women of Balochistan origin.
Baloch AH; Daud S; Raheem N; Luqman M; Ahmad A; Rehman A; Shuja J; Rasheed S; Ali A; Kakar N; Naseeb HK; Mengal MA; Awan MA; Wasim M; Baloch DM; Ahmad J
Mol Biol Rep; 2014 Feb; 41(2):1103-7. PubMed ID: 24390236
[TBL] [Abstract][Full Text] [Related]
40. CHEK2 1100delC variant and breast cancer risk in Caucasians: a meta-analysis based on 25 studies with 29,154 cases and 37,064 controls.
Yang Y; Zhang F; Wang Y; Liu SC
Asian Pac J Cancer Prev; 2012; 13(7):3501-5. PubMed ID: 22994785
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
